On To Phase II Trials For JAK2, Singapore's S*BIO Reports

PERTH, Australia - Singapore-based biotech S*BIO reported positive data on its Phase I trials for its Janus kinase 2 inhibitor SB1518 at the American Society of Hematology annual meeting in New Orleans Dec. 7